Massive study pits tirzepatide against rivals for heart protection
NCT ID NCT06779929
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at insurance claims data from 70,000 people with type 2 diabetes and established heart disease to compare the heart-related risks of three diabetes drugs: tirzepatide, dulaglutide, and semaglutide. The goal was to see if any of these drugs was linked to fewer heart attacks, strokes, or deaths. Because it used existing data rather than a controlled experiment, the findings can suggest but not prove which drug might be safer for the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tirzepatide, dulaglutide, semaglutide
- What this could lead to
- If this study shows one drug is better at preventing heart attacks or strokes, it could guide doctors to choose the most effective treatment for people with type 2 diabetes and heart disease.
- What could go wrong
- This is an observational study using insurance claims, not a randomized trial, so results may be influenced by unmeasured factors. It cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?